In a sudden management revamp, Celgene President and COO Scott Smith will leave his post at the biotech company, effective immediately. Celgene has recently suffered from a series of major setbacks ...

Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial This academic, investigator-initiated ...

Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached. Avila’s therapeutic platform involves the development of ...

Flatiron Health, a New York City-based oncology technology company, has expanded its relationships with biotechnology company Celgene Corp. and biopharmaceutical company Amgen. Here are three things ...

Celgene’s shares have dropped nearly 30 percent since October, due to slow sales of its psoriasis drug Otezla, an upcoming patent cliff for its multiple myeloma drug Revlimid, and the failure of an ...

Seattle's NanoString Technologies ($NSTG) stands to make up to $45 million if it can come up with a successful companion diagnostic test to screen for a subset of ...

US biotech firm Celgene on Monday announced a deal to acquire the bio-pharmaceutical company Juno Therapeutics for $9 billion or $87 per share. The Seattle-based Juno is a leader in developing ...